Back to Search
Start Over
Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases.
- Source :
-
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2015 Apr 09; Vol. 34, pp. 33. Date of Electronic Publication: 2015 Apr 09. - Publication Year :
- 2015
-
Abstract
- Background: Metastatic spread of tumor cells remains a serious problem in cancer treatment. Gene-directed enzyme/prodrug therapy mediated by tumor-homing genetically engineered mesenchymal stromal cells (MSC) represents a promising therapeutic modality for elimination of disseminated cells. Efficacy of gene-directed enzyme/prodrug therapy can be improved by combination of individual systems. We aimed to define the combination effect of two systems of gene therapy mediated by MSC, and evaluate the ability of systemically administered genetically engineered mesenchymal stromal cells to inhibit the growth of experimental metastases derived from human breast adenocarcinoma cells MDA-MB-231/EGFP.<br />Methods: Human adipose tissue-derived mesenchymal stromal cells (AT-MSC) were retrovirally transduced with fusion yeast cytosine deaminase::uracil phosphoribosyltransferase (CD::UPRT) or with Herpes simplex virus thymidine kinase (HSVtk). Engineered MSC were cocultured with tumor cells in the presence of prodrugs 5-fluorocytosin (5-FC) and ganciclovir (GCV). Combination effect of these enzyme/prodrug approaches was calculated. SCID/bg mice bearing experimental lung metastases were treated with CD::UPRT-MSC, HSVtk-MSC or both in combination in the presence of respective prodrug(s). Treatment efficiency was evaluated by EGFP-positive cell detection by flow cytometry combined with real-time PCR quantification of human cells in mouse organs. Results were confirmed by histological and immunohistochemical examination.<br />Results: We demonstrated various extent of synergy depending on tested cell line and experimental setup. The strongest synergism was observed on breast cancer-derived cell line MDA-MB-231/EGFP. Systemic administration of CD::UPRT-MSC and HSVtk-MSC in combination with 5-FC and GCV inhibited growth of MDA-MB-231 induced lung metastases.<br />Conclusions: Combined gene-directed enzyme/prodrug therapy mediated by MSC exerted synergic cytotoxic effect and resulted in high therapeutic efficacy in vivo.
- Subjects :
- Animals
Cell Line, Tumor
Disease Models, Animal
Humans
Lung Neoplasms secondary
Lung Neoplasms therapy
Mesenchymal Stem Cell Transplantation
Mice
Moloney murine leukemia virus genetics
Xenograft Model Antitumor Assays
Ganciclovir pharmacology
Genetic Therapy
Lung Neoplasms pathology
Mesenchymal Stem Cells metabolism
Thymidine Kinase genetics
Transduction, Genetic
Subjects
Details
- Language :
- English
- ISSN :
- 1756-9966
- Volume :
- 34
- Database :
- MEDLINE
- Journal :
- Journal of experimental & clinical cancer research : CR
- Publication Type :
- Academic Journal
- Accession number :
- 25884597
- Full Text :
- https://doi.org/10.1186/s13046-015-0149-2